Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.53 |
| ▸ | FNTA | P49354 | 5/20 | 0.51 |
| ▸ | FNTB | P49356 | 5/20 | 0.51 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8368375 | 0.99 | CYP11B1 (0.52) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL5892040 | 0.86 | CYP11B1 (0.51) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL5891919 | 0.82 | FNTA (0.55) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Hydrochloric Acid SCHEMBL8541204 | 0.81 | FNTA (0.55) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL6714988 | 0.81 | FNTA (0.53) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL13686692 | 0.75 | FNTA (0.57) | CYP11B1CYP11B2FNTAFNTB | |
| SCHEMBL5892034 | 0.75 | FNTA (0.55) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL13686701 | 0.74 | FNTA (0.57) | CYP11B1CYP11B2FNTAFNTB | |
| Hydrochloric Acid SCHEMBL9051605 | 0.74 | FNTA (0.54) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL13686687 | 0.74 | FNTA (0.57) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989383-B1 | Method of treating cancer | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-01-24 | — | — | US | claimed |
| US-20050277629-A1 | Methods for the treatment of synucleinopathies (Lansbury) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-12-15 | — | — | US | claimed |
| US-20050137207-A1 | Method of treating cancer | ROSEN NEAL (US) | 2005-06-23 | — | — | US | claimed |
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | claimed |
| EP-0841919-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-02-24 | — | — | EP | claimed |
| EP-0841919-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-05-20 | — | — | EP | claimed |
| US-5710171-A | ANTICANCER AND ANTITUMOR AGENTS | MERCK & CO., INC. (US) | 1998-01-20 | — | — | US | claimed |
| WO-1996037204-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-11-28 | — | — | WO | claimed |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2010057028-A9 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | LINK MEDICINE CORPORATION (MA) | 2010-07-22 | — | — | US | disclosed |
| WO-2010057028-A2 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2155197-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | Link Medicine Corporation (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008112525-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | LINK MEDICINE CORPORATION (US) | 2008-09-18 | — | — | WO | disclosed |
| EP-0986302-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-03-22 | — | — | EP | disclosed |
| EP-0841919-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-02-24 | — | — | EP | disclosed |
| WO-1998054966-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1998-12-10 | — | — | WO | disclosed |
| EP-0841919-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-05-20 | — | — | EP | disclosed |
| US-5710171-A | ANTICANCER AND ANTITUMOR AGENTS | MERCK & CO., INC. (US) | 1998-01-20 | — | — | US | disclosed |
| WO-1996037204-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | CYP11B1 530/4885CYP11B2 621/4885FNTA 4/4885 |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | GAA, GBA1, MAN2B1 | CYP11B1 4060/4885CYP11B2 4313/4885FNTA 19/4885 |
| US-20050277629-A1 | Methods for the treatment of synucleinopathies (Lansbury) | SNCA, PARK7, NLN | CYP11B1 1230/4885CYP11B2 1100/4885FNTA 12/4885 |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | FNTA, FNTB, BDNF | CYP11B1 2067/4885CYP11B2 2662/4885FNTA 1/4885 |
| US-20050137207-A1 | Method of treating cancer | FNTA, GGT1, NTPCR | CYP11B1 515/4885CYP11B2 578/4885FNTA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.